3.9 Article

Postoperative Radiotherapy in Head and Neck Mucosal Melanoma A GETTEC Study

期刊

ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY
卷 136, 期 12, 页码 1219-1225

出版社

AMER MEDICAL ASSOC
DOI: 10.1001/archoto.2010.217

关键词

-

向作者/读者索取更多资源

Objective: To report patterns of failure according to treatment modality, with an emphasis on the role of postoperative radiotherapy in patients with localized head and neck mucosal melanoma (HNMM) treated during a 28-year period in a multi-institutional setting. Design: Retrospective review. Setting: French medical institutions. Patients: A total of 160 patients with nonmetastatic HNMM treated from 1980 through 2008. Interventions: Treatment modality consisted of surgery alone (hereinafter, S group) (n=82 patients) or with postoperative radiotherapy (hereinafter, SRT group) (n=78). Patients and tumor characteristics were similar in the 2 groups. There was a nonsignificant trend (P=.11) for more locally advanced tumor stage (38.9%) in the SRT group compared with the S group (24.5%). Results: Patients in the S group had an increased probability of locoregional recurrence as a first event (55.6%) compared with those in the SRT group (29.9%; P<.01). After adjusting for tumor stage (T1/T2 vs T3/T4), the subdistribution hazard ratio of locoregional relapse was 0.31, (95% confidence interval [CI], 0.15-0.61; P<.01). The rate of distant metastasis as a first event was significantly higher in the SRT group (40.6%) compared with the S group (19.9%; P=.01). Regardless of their treatment, patients who had a locoregional relapse during follow-up had an increased risk of subsequent distant metastasis (hazard ratio, 3.07; 95% CI, 1.65-5.67) and death (hazard ratio, 3.01; 95% CI, 1.91-4.78). Conclusions: This large retrospective study suggests that postoperative radiotherapy improves the locoregional control of HNMM. The higher rate of distant metastasis was due to more advanced disease in the SRT group. Arch Otolaryngol Head Neck Surg. 2010;136(12):1219-1225

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

3.9
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

Multicenter study to assess surgical treatments of 452 sinonasal intestinal-type adenocarcinomas: A REFCOR study

Ludovic de Gabory, Alice Waubant, Benjamin Verillaud, Justin Michel, Olivier Malard, Cecile Rumeau, Roger Jankowski, Antoine Moya-Plana, Sebastien Vergez, Valentin Favier, Geoffrey Mortuaire, Christian Righini, Vincent Patron, Juliette Thariat, Charles Dupin, Julien Coelho, Antoine Benard

Summary: This study compared the local oncological outcomes of endoscopic and external surgical treatment for sinonasal intestinal-type adenocarcinomas and identified factors associated with recurrence. The results showed that the endoscopic approach had better surgical margins, lower recurrence rate, and fewer surgical complications. The invasion of surgical margins and the presence of signet-ring cells were identified as independent factors of recurrence.
Article Oncology

FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1/3 mRNA Expression

Cora N. Sternberg, Daniel P. Petrylak, Joaquim Bellmunt, Hiroyuki Nishiyama, Andrea Necchi, Howard Gurney, Jae-Lyun Lee, Michiel S. van der Heijden, Eli Rosenbaum, Nicolas Penel, See-Tong Pang, Jian-Ri Li, Xavier Garcia del Muro, Florence Joly, Zsuzsanna Papai, Weichao Bao, Peter Ellinghaus, Chengxing Lu, Mitchell Sierecki, Sabine Coppieters, Keiko Nakajima, Tatiane Cristine Ishida, David Quinn

Summary: The purpose of this study was to assess the efficacy and safety of rogaratinib compared to chemotherapy in patients with FGFR-positive advanced/metastatic UC. The results showed comparable overall survival and response rates between rogaratinib and chemotherapy, with manageable side effects. Exploratory analysis suggested that FGFR3 gene alterations may be better predictors of rogaratinib response in FGFR-altered UC patients.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Article Oncology

Survival outcomes, prognostic factors, and effect of adjuvant radiotherapy and prophylactic neck dissection in salivary acinic cell carcinoma: A prospective multicenter REFCOR study of 187 patients

Florian Chatelet, Francois Regis Ferrand, Sarah Atallah, Juliette Thariat, Francois Mouawad, Nicolas Fakhry, Olivier Malard, Caroline Even, Erwan de Mones, Emmanuelle Uro-Coste, Nazim Benzerdjeb, Stephane Hans, Sylvie Testelin, Olivier Mauvais, Diane Evrard, Vianney Bastit, Sebastien Salas, Florent Espitalier, Marion Classe, Laurence Digue, Melanie Dore, Stephanie Wong, Charles Dupin, France Nguyen, Jeremie Bettoni, Ariane Lapierre, Emilien Colin, Pierre Philouze, Sebastien Vergez, Bertrand Baujat, Philippe Herman, Benjamin Verillaud

Summary: This study analyzed data from the national REFCOR multi-center cohort to investigate the prognostic factors in acinic cell carcinomas (AciCCs) and assess the impact of postoperative radiotherapy and prophylactic neck dissection. The results suggest the importance of long-term follow-up in AciCC patients and indicate that surgery alone may be an option for selected patients without high-grade transformation. Prophylactic neck dissection may be beneficial for patients with advanced stage or high-grade tumors.

EUROPEAN JOURNAL OF CANCER (2023)

Article Medicine, General & Internal

Enteral Nutrition during Radiotherapy for Oropharyngeal Cancers: Prevalence and Prognostic Factors Based on HPV Status (A GETTEC Study)

Dorian Culie, Renaud Schiappa, Tanguy Pace-Loscos, Bruno Guelfucci, Sebastien Vergez, Renaud Garrel, Nicolas Fakhry, Olivier Dassonville, Gilles Poissonnet, Benjamin Lallemant, Anne Sudaka, Esma Saada-Bouzid, Karen Benezery, Stephane Temam, Phillipe Gorphe, Emmanuel Chamorey, Alexandre Bozec

Summary: Nutritional support is crucial for tolerating and completing OPSCC treatment, but the impact of HPV status on nutritional support is debated. This study aimed to evaluate the use of RFT and its prognostic factors in OPSCC patients undergoing radiotherapy. A multicentric retrospective study included all OPSCC patients treated from 2009 to 2014. Multivariate analysis showed that tongue base involvement and concurrent chemotherapy were significantly associated with the use of RFT. HPV status was not a prognostic factor for enteral nutrition during radiotherapy for OPSCC.

JOURNAL OF CLINICAL MEDICINE (2023)

Review Medicine, General & Internal

Transoral Robotic Surgery for Head and Neck Cancer: Advances and Residual Knowledge Gaps

Mariam H. Mella, Emilien Chabrillac, Agnes Dupret-Bories, Mathilde Mirallie, Sebastien Vergez

Summary: Minimally invasive surgery, specifically transoral robotic surgery (TORS), has become popular in the field of surgical oncology for the treatment of head and neck cancer. TORS utilizes wristed instruments and a magnified three-dimensional view for enhanced surgical comfort and safety in hard-to-access areas. However, the expansion of TORS must be based on high-level evidence to ensure comparable oncological outcomes to traditional approaches. This narrative review evaluates the current role of TORS in head and neck cancer treatment and identifies remaining knowledge gaps.

JOURNAL OF CLINICAL MEDICINE (2023)

Article Medicine, General & Internal

Transoral Laser Microsurgery versus Robot-Assisted Surgery for Squamous Cell Carcinoma of the Tongue Base (Oncological and Functional Results)-A Retrospective GETTEC Multicenter Study

Ioana Brudasca, Pierre Philouze, Sylvain Moriniere, Benjamin Lallemant, Sebastien Vergez, Olivier Malard, Pierre-Eric Roux, Noemie Rossello, Caroline Payen, Philippe Ceruse

Summary: This study compared two minimally invasive approaches, transoral laser microsurgery (TLM) and transoral robot-assisted surgery (TORS), for the treatment of squamous cell carcinoma (SCC) in the base of the tongue (BOT). The study found no significant difference in oncological outcomes between the two techniques, with TORS removing larger tumors but having shorter operative times. Both TLM and TORS were found to be effective treatment options for BOT SCC.

JOURNAL OF CLINICAL MEDICINE (2023)

Letter Oncology

Why will there never be a randomized trial for NTRK-rearranged tumors?

N. Penel, L. Lebellec, J. -y. Blay

ANNALS OF ONCOLOGY (2023)

Article Oncology

Regorafenib in patients with advanced Ewing sarcoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre Phase II study

Florence Duffaud, Jean-Yves Blay, Axel Le Cesne, Christine Chevreau, Pascaline Boudou-Rouquette, Elsa Kalbacher, Nicolas Penel, Christophe Perrin, Valerie Laurence, Emmanuelle Bompas, Esma Saada-Bouzid, Corinne Delcambre, Francois Bertucci, Mathilde Cancel, Camille Schiffler, Laure Monard, Corinne Bouvier, Vincent Vidal, Nathalie Gaspar, Sylvie Chabaud

Summary: Although the primary endpoint was not met statistically in this randomised cohort, there is evidence to suggest that regorafenib might modestly delay tumour progression in relapsed ES after failure of prior chemotherapy.

BRITISH JOURNAL OF CANCER (2023)

Article Oncology

Randomized phase III trial of metabolic imaging-guided dose escalation of radio-chemotherapy in patients with newly diagnosed glioblastoma (SPECTRO GLIO trial)

Anne Laprie, Georges Noel, Leonor Chaltiel, Gilles Truc, Marie-Pierre Sunyach, Marie Charissoux, Nicolas Magne, Pierre Auberdiac, Julian Biau, Soleakhena Ken, Fatima Tensaouti, Jonathan Khalifa, Ingrid Sidibe, Franck-Emmanuel Roux, Laure Vieillevigne, Isabelle Catalaa, Sergio Boetto, Emmanuelle Uro-Coste, Stephane Supiot, Valerie Bernier, Thomas Filleron, Muriel Mounier, Muriel Poublanc, Pascale Olivier, Jean-Pierre Delord, Elizabeth Cohen-Jonathan-Moyal

Summary: MRSI-guided dose escalation in newly diagnosed GBM patients did not improve overall survival (OS).

NEURO-ONCOLOGY (2023)

Article Oncology

Impact of the coronavirus disease 2019 pandemic on sarcoma management in France: a 2019 and 2020 comparison

Nicolas Penel, Coralie Cantarel, Claire Chemin-Airiau, Francoise Ducimetiere, Francois Gouin, Francois Le Loarer, Maud Toulmonde, Sophie Piperno-Neumann, Carine Bellera, Charles Honore, Jean-Yves Blay, Simone Mathoulin-Pelissier

Summary: This study reveals that the incidence of limb and trunk soft tissue sarcomas did not decrease during the COVID-19 pandemic, and there was an increase in the number of surgeries performed in labeled centers. Quality indicators, such as the rate of R0 resection, also improved during the pandemic. This highlights the resilience of the nationwide network organization in managing rare tumors during the pandemic.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2023)

Review Oncology

Predictive biomarkers for immune checkpoint inhibitor response in urothelial cancer

Pauline Parent, Gautier Marcq, Sola Adeleke, Anthony Turpin, Stergios Boussios, Elie Rassy, Nicolas Penel

Summary: Immune checkpoint inhibitors (ICIs) are commonly used for treating advanced urothelial cancer, but a significant number of patients do not respond to them, and the lack of validated predictive biomarkers hinders the success of ICI strategy. Identifying biomarkers of response to ICI is crucial for guiding treatment decisions. The most evaluated biomarkers include programmed death ligand 1 expression, microsatellite instability/defective mismatch repair phenotype, and tumor mutational burden.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2023)

Article Oncology

Intracranial Solitary Fibrous Tumour Management: A French Multicentre Retrospective Study

Marine Lottin, Alexandre Escande, Luc Bauchet, Marie Albert-Thananayagam, Mael Barthoulot, Matthieu Peyre, Mathieu Boone, Sonia Zouaoui, Jacques Guyotat, Guillaume Penchet, Johan Pallud, Henry Dufour, Evelyne Emery, Michel Lefranc, Sebastien Freppel, Houman Namaki, Edouard Gueye, Jean-Jacques Lemaire, Bertrand Muckensturm, Robin Srour, Stephane Derrey, Apolline Monfilliette, Jean-Marc Constans, Claude-Alain Maurage, Bruno Chauffert, Nicolas Penel

Summary: This retrospective study analyzed the clinical outcomes of 88 patients with intracranial solitary fibrous tumours (iSFTs). Gross tumour resection was found to be beneficial for prognosis and reduced local recurrence without impacting overall survival. High-grade tumours were associated with poorer progression-free survival and local recurrence-free survival. More than 40% of patients experienced local recurrence and were mostly treated with surgery and radiotherapy. The first relapse was a turning point in iSFT evolution, with shorter recurrence intervals over time. Managing repeated recurrence and disseminated disease remains challenging and local techniques should be considered.

CANCERS (2023)

Article Oncology

Management of 80 sinonasal undifferentiated carcinomas. Retrospective multicentre study of the French Network of Rare Head and Neck Cancers (REFCOR)

Pierre Pouvreau, Julien Coelho, Cecile Rumeau, Olivier Malard, Renaud Garrel, Justin Michel, Christian Righini, Sebastien Vergez, Robin Baudouin, Vianney Bastit, Jean-Paul Marie, Aude Villepelet, Antoine Moya-Plana, Pierre Philouze, Nicolas Saroul, Laurence Digue, Amaury Daste, Sophie Renard, Sylvain Moriniere, Florent Carsuzaa, Benjamin Verillaud, Gilles Poissonnet, Philippe Schultz, Esteban Brenet, Francois Mouawad, Juliette Thariat, Noemie Vulquin, Claire Castain, Ludovic de Gabory, Charles Dupin

Summary: This study aimed to explore the treatment and prognostic factors of sinonasal undifferentiated carcinoma (SNUC). The results showed that surgery did not benefit overall survival in SNUC patients treated with irradiation, while the addition of chemotherapy tended to improve disease-free survival.
暂无数据